Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Thompson

Showing results (571-580 of 637) with videos related to

Pageof 64
Sort By:
Hypertension (Dallas, Tex. : 1979)|March 22, 2021
Reference Intervals for Brachial Artery Flow-Mediated Dilation and the Relation With Cardiovascular Risk FactorsSophie M Holder, Rosa Maria Bruno, Daria A Shkredova, et al.
Schizophrenia Bulletin|March 4, 2023
Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode ParticipantsTil Wykes, Dominic Stringer, Janette Boadu, et al.
Nature Biomedical Engineering|December 22, 2022
Treatment of peanut allergy and colitis in mice via the intestinal release of butyrate from polymeric micellesRuyi Wang, Shijie Cao, Mohamed Elfatih H Bashir, et al.
Schizophrenia (Heidelberg, Germany)|September 30, 2023
Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scaleJoanne Evans, Rose Tinch-Taylor, Emese Csipke, et al.
Early Intervention in Psychiatry|October 5, 2022
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study)Brian O'Donoghue, Kelly Allott, Susy Harrigan, et al.
JAMA Neurology|February 24, 2016
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob DiseaseSimon Mead, Matthew Burnell, Jessica Lowe, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 26, 2025
Exploring the interconnections between baseline symptoms in ultra-high risk youth who did and did not transition to psychosis over three years: A network analysis comparisonGabriele Lo Buglio, Simon Hartmann, Tommaso Boldrini, et al.
Schizophrenia Research. Cognition|March 14, 2022
Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspectiveImogen Bell, Roos M C A Pot-Kolder, Stephen J Wood, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Pageof 64

Showing results (571-580 of 637) with videos related to

Sort By:
Pageof 64
Hypertension (Dallas, Tex. : 1979)|March 22, 2021
Reference Intervals for Brachial Artery Flow-Mediated Dilation and the Relation With Cardiovascular Risk FactorsSophie M Holder, Rosa Maria Bruno, Daria A Shkredova, et al.
Schizophrenia Bulletin|March 4, 2023
Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode ParticipantsTil Wykes, Dominic Stringer, Janette Boadu, et al.
Nature Biomedical Engineering|December 22, 2022
Treatment of peanut allergy and colitis in mice via the intestinal release of butyrate from polymeric micellesRuyi Wang, Shijie Cao, Mohamed Elfatih H Bashir, et al.
Schizophrenia (Heidelberg, Germany)|September 30, 2023
Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scaleJoanne Evans, Rose Tinch-Taylor, Emese Csipke, et al.
Early Intervention in Psychiatry|October 5, 2022
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study)Brian O'Donoghue, Kelly Allott, Susy Harrigan, et al.
JAMA Neurology|February 24, 2016
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob DiseaseSimon Mead, Matthew Burnell, Jessica Lowe, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 26, 2025
Exploring the interconnections between baseline symptoms in ultra-high risk youth who did and did not transition to psychosis over three years: A network analysis comparisonGabriele Lo Buglio, Simon Hartmann, Tommaso Boldrini, et al.
Schizophrenia Research. Cognition|March 14, 2022
Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspectiveImogen Bell, Roos M C A Pot-Kolder, Stephen J Wood, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Pageof 64